- Telehealth Visits
- Insurance plan information
Daniel Minter, MD
He | Him | HisInfectious Diseases • Neuro-Infectious Disease- Telehealth Visits
- Insurance plan information
Daniel Minter, MD
He | Him | HisInfectious Diseases • Neuro-Infectious Disease- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Daniel Minter is an infectious disease specialist who cares for patients with a broad range of bacterial, fungal, viral and parasitic infections. He has special interests in caring for immunocompromised patients and those with infections that affect the nervous system.
Minter's research interests include medical education and clinical reasoning (the thought processes through which care providers diagnose conditions and develop treatment plans). He teaches medical students, residents and fellows in a variety of settings.
Minter earned his medical degree at UCSF, where he also completed a residency in internal medicine and a fellowship in infectious diseases.
Education & training
Board certification
- Infectious Disease, American Board of Internal Med/Infectious Disease
- Internal Medicine, American Board of Internal Medicine
Fellowship
- Infectious Diseases, UCSF Graduate Medical Education
Residency
- Internal Medicine, UCSF Graduate Medical Education
Internship
- Internal Medicine, UCSF Graduate Medical Education
Degree
- MD, UCSF School of Medicine
My expertise
Specialties
Locations
Clinical Trials query: q=health_gateway_id_ss%3A%28%223113%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%223113%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.